Bruker (NASDAQ:BRKR – Get Free Report) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 2.100-2.150 for the period, compared to the consensus earnings per share estimate of 2.120. The company issued revenue guidance of $3.5 billion-$3.6 billion, compared to the consensus revenue estimate of $3.6 billion.
Analysts Set New Price Targets
BRKR has been the topic of several analyst reports. UBS Group set a $60.00 price target on Bruker in a research report on Wednesday, June 24th. Wall Street Zen raised Bruker from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Citigroup dropped their price objective on shares of Bruker from $60.00 to $53.00 and set a “neutral” rating on the stock in a research note on Wednesday. TD Cowen reiterated a “hold” rating on shares of Bruker in a research note on Wednesday, July 15th. Finally, Guggenheim raised their price target on shares of Bruker from $50.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Bruker presently has a consensus rating of “Moderate Buy” and an average price target of $56.64.
Get Our Latest Research Report on BRKR
Bruker Stock Performance
Bruker (NASDAQ:BRKR – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.11. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The business had revenue of $838.50 million during the quarter, compared to the consensus estimate of $853.57 million. During the same period in the previous year, the firm posted $0.32 earnings per share. The business’s revenue was up 5.2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, sell-side analysts forecast that Bruker will post 2.12 EPS for the current fiscal year.
Bruker Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd were given a $0.05 dividend. The ex-dividend date was Monday, June 22nd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. Bruker’s dividend payout ratio (DPR) is currently -83.33%.
Bruker News Summary
Here are the key news stories impacting Bruker this week:
- Positive Sentiment: Bruker reported second-quarter adjusted EPS of $0.49, above the $0.38 analyst consensus and up from $0.32 a year earlier. Revenue increased 5.2% year over year to $838.5 million. Bruker Q2 Earnings Beat Estimates
- Positive Sentiment: Zacks Research upgraded BRKR from “hold” to “strong buy,” providing a positive counterpoint to the broader analyst reaction. Zacks.com
- Positive Sentiment: Management highlighted margin strength on the earnings call, while maintaining fiscal 2026 adjusted EPS guidance of $2.10 to $2.15, broadly in line with the $2.12 consensus. Bruker Earnings Call Highlights Margin Strength
Hedge Funds Weigh In On Bruker
Several hedge funds and other institutional investors have recently modified their holdings of BRKR. Los Angeles Capital Management LLC acquired a new position in Bruker in the fourth quarter valued at $26,000. Allworth Financial LP raised its position in shares of Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after buying an additional 257 shares in the last quarter. Parallel Advisors LLC boosted its position in shares of Bruker by 121.0% during the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 479 shares during the last quarter. Summit Securities Group LLC bought a new position in shares of Bruker in the 4th quarter worth $50,000. Finally, Parkside Financial Bank & Trust increased its stake in Bruker by 144.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,482 shares of the medical research company’s stock valued at $70,000 after acquiring an additional 876 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.
About Bruker
Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.
Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.
In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.
Featured Stories
- Five stocks we like better than Bruker
- Boeing’s Comeback Is Building Momentum—Is It Real?
- Blueprint for a Banking Fortress: Circle Redraws the Map
- Bed Bath & Beyond Renovates: The Neighborhood Blueprint
- These Outperforming Giants Are Boosting Dividends in 2026, With Yields of Up to 6.6%
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.
